Laparoscopic Splenectomy for Benign Splenic Tumor:another Golden Standard

Ali Wajid, PhD, Yongbin Li, PhD, Bing Peng, PhD. Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University.

Introduction: There is a paucity of data about evaluation and laparoscopic management for benign splenic tumors. We hypothesized that LS is feasible, safe, and effective in patients with benign splenic tumors.

Method: In this study, we retrospectively reviewed 29 laparoscopic splenectomy patients (group 1), 25 open splenectomy patients (group 2) with benign splenic tumors, and 46 laparoscopic splenectomy patients (group 3) with immune thrombocytopenic purpura as reference group from 2007 to 2011.

Results: Patients in group 1 and 2 had comparable preoperative details. Outcomes for group1 had less estimated blood loss (88±31ml vs 133±92ml, P=0.029), fewer complications (10.3% vs 36%, P=0.024), less time of returning to oral intake (17.6±2.6hours vs 25.2±2.7hours, P=0), and required less analgesia (13% vs 60%, P=0). Compared with patients in group 3, patients in group1 had larger splenic size (13.6±2.6cm vs 11.2±2.2cm, P=0), higher platelet count (147±43 vs 23±25, P=0), and better ASA class. However, there were no significant differences in terms of intraoperaive and postoperative valuables.

Conclusion: We conclude that laparoscopic splenectomy is superior to opne splenectomy in patients with benign splenic tumors, and also that outcomes for LS treated benign splenic tumor patients were safe, feasible, and effective.

View Poster

« Return to SAGES 2014 abstract archive